sur Immunic AG
Immunic Secures USD 400 Million to Advance Commercial Ambitions
Immunic AG announced the successful completion of an oversubscribed private placement, raising up to USD 400 million. The initial USD 200 million is earmarked to conclude the Phase 3 ENSURE trials for relapsing multiple sclerosis and start trials for primary progressive multiple sclerosis, aiding its transition into a commercial-stage entity.
Key leadership changes accompany this strategic shift. Simona Skerjanec, a former Roche executive, is appointed interim Chairperson of the Board. Thor Nagel of BVF Partners joins the Board to guide the company’s commercial transformation. Additionally, a new CEO with a commercial background will be recruited.
The financing, supported by BVF Partners and other investors, underscores Immunic's commitment to developing vidofludimus calcium, a potential game-changer in multiple sclerosis treatment.
With strategic leadership and financial reinforcement, Immunic aims to enhance neurologic health innovations.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Immunic AG